KMTS

Rating neutralAI MemoPost-earnings T+3

Kestra Medical

As of 2026-07-17/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

FY26 results and FY27 revenue guide • 2026-07-14

Expected move: +11%

Biggest risk

The company remains loss-making, adjusted EBITDA loss widened to $26.7 million in Q4, and accelerated commercial investment raises execution and financing sensitivity.

Invalidation

Break below $18 or thesis failure.

What would change my mind?

Strong revenue growth, improving gross margin, rising prescriptions, and FY27 guidance support continued commercialization upside.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-17

Base target

$27

p=50%

Bull target

$32

p=25%

Bear target

$18

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Prescription and market-share expansion
Margin improvement durability
Strong revenue growth, improving gross margin, rising prescriptions, and FY27 guidance support continued commercialization upside.

BearKey bullets

Adjusted EBITDA losses and higher commercial-expansion expenses may delay operating leverage.
Execution risk against the $137 million FY27 revenue guide.
New Tranche A financing provided approximately $20 million of net proceeds but increases balance-sheet and refinancing sensitivity.

WatchKey bullets

FY26 results and FY27 revenue guide

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $27 (p=50%)

Bull/Bear spread: +31% / -26%

Vs latest close: Bull +31% · Base +11% · Bear -26%

Scenario probabilities

Bull Target: $32 (p=25%)Base Target: $27 (p=50%)Bear Target: $18 (p=25%)

Commentary

The earnings release tone is constructive, but the evidence is concentrated in company/SEC reporting. The July 16 anchor price was $23.98; analyst revision data, options positioning, short interest, employee sentiment, and a verified post-print reaction are unavailable, so conviction remains moderate and monitoring-oriented.

As of 2026-07-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Strong revenue growth, improving gross margin, rising prescriptions, and FY27 guidance support continued commercialization upside.

Bear Case

The company remains loss-making, adjusted EBITDA loss widened to $26.7 million in Q4, and accelerated commercial investment raises execution and financing sensitivity.

Drivers

Scannable catalysts and supporting factors

Prescription and market-share expansion
Margin improvement durability

Scenarios

Bull Target (Scenario probability)

$32 / p=25% prob

Base Target (Scenario probability)

$27 / p=50% prob

Bear Target (Scenario probability)

$18 / p=25% prob

Price $24 as of 2026-07-17

Nearest Scenario: Base (∆ 11%)

Targets vs latest close: Bull +31% · Base +11% · Bear -26%

Sentiment & Exposure

News Sentiment (30d)

0.50

Social Sentiment (7d)

0.50

Events

Other notable items detected

EVENT2026-07-14
FY26 results and FY27 revenue guide
Q4 revenue rose 66% to $28.6 million, gross margin expanded to 54.8%, and FY27 revenue guidance was set at $137 million, up 44% from FY26. [#SEC-8K-2026-07-14]
Prob 100.00% • Move 12.00% • Priced-in 85.00%
EVENT2026-10-15
Product and collaboration execution
Management cited progress on FDA post-approval study results, an algorithm update, commercial expansion, and a strategic collaboration with Biobeat; the packet does not provide enough detail to assign a high-conviction milestone value. [#SEC-8K-2026-07-14]
Prob 40.00% • Move 8.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Prescription and market-share expansion
2027-07-17
Q4 ASSURE prescriptions increased 63% to 6,357; management attributed growth primarily to higher market share and wearable cardioverter-defibrillator market expansion. [#SEC-8K-2026-07-14]
Prob 65% • Move 18% • Priced-in 60%
Margin improvement durability
2027-07-17
Gross-margin gains reflected volume leverage, a higher in-network patient mix, and planned cost-improvement programs. Sustaining these gains is a key monitorable for the growth thesis. [#SEC-8K-2026-07-14]
Prob 55% • Move 10% • Priced-in 55%

Risks

Adjusted EBITDA losses and higher commercial-expansion expenses may delay operating leverage.
Execution risk against the $137 million FY27 revenue guide.
New Tranche A financing provided approximately $20 million of net proceeds but increases balance-sheet and refinancing sensitivity. [#8-K-2026-07-14]
Post-earnings analyst revisions and an independently verified market-reaction attribution are unavailable.
Repeated open-market sales by CEO Brian Webster are a secondary sentiment overhang, not evidence of operating performance. [#SEC-FORM4-2026-06-17]

Peers

Symbol	Summary
ATEC	Size-matched same-sector medtech comparator from the candidate set; the packet lacks enough operating detail for a strong relative valuation conclusion.
CNMD	Size-matched same-sector medical-device comparator; useful for monitoring but business comparability and valuation evidence remain limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-07-17

AI Stock Memo: KMTS - Kestra Medical - RankAlpha